Compare Ford Motor Company (F) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Novo Nordisk A/S — how do they compare? Ford Motor Company trades at $14.12 (market cap $56.50B), while Novo Nordisk A/S trades at $51.49 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 3.9× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.23%). Which is the better fit depends on your goals.
| F | NVO | |
|---|---|---|
Market Cap | $56.50B | $222.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $71.70 |
52-Week Low | $10.82 | $35.29 |
Enterprise Value | $185.53B | $241.20B |
Dividend Yield | 4.23% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford (F) trades at $14.09, up 1.15% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.00. Recent earnings show volatility with Q1 2026 beating expectations but Q4 2025 missing, while revenue grew to $187.27 billion in 2025. The company maintains strong cash flow from operations at $21.28 billion and announced a $0.15 dividend for H1 2026, though net income was negative at -$8.18 billion due to high costs.
Ford's outlook is mixed, with opportunities from EV expansion and labor stability, but risks include profit margin pressure and rising debt. Analysts are cautiously optimistic with 34% buy ratings, yet investors should weigh competitive threats and macroeconomic headwinds against the stock's low P/E of 11.84 and dividend yield.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
